thanks for that good to see vesty super increasing the holding as the share price appreciated rather the sell down boy the free float is going to make it hard for an insto to get on board before phase three if at most they only need circa $10 m for phase 2 if the cap raise is spread a bit 5 of them would likely get less than 2$ mill ea i expect some to be forced to enter the market soon collins st fund managers said they entered par early phase 2 ( unusually for them) as the evidence for success exhibited by tga special access trials was overwhelming efficacy its hard for recce to be accessed via similar GP tga application as its a hospital iv application to v sick sepsis patients and hospitals very very reluctant to use non fda approved drugs for even life critical situations so apart from upcoming possible covid CSIRO tests in vivo in vitro etc in non humans, we need to look elsewhere for such confirmation all pre clinical bacteria and virus tests have exhibited exceptionsl efficacy and no toxic indications even at 10 - 100 times expected efficacy dosages tests on humans for taking preclinical gonnoreha tests are likely to be a lot faster to gain approval for use same with outstanding results on urinary tract infections all serious concerns over bacterial resistance to current penecillin based drugs the first up for human use is i reckon human trials in burn and other open skin wound exposures where rec327 has shown superior non toxic performance in mice etc all these parameters going on concurrently provide a very rich news agenda over this year and next at this mc under $300 m i reckon a major undervalued risk valuation is still priced into the market after reading in detail the recent imu presentation for investors on values applied to small - mid cap bio pharma- to big big cap pharma $350 seems the lower bar $1.5 the upper for where recce is right now if one realistically applies the depth of the market on all these possible unmet medical issues from which millions are dying the numbers are truly extraordinary ! even a 10 pct penetration like collins st fund managers applied to PAR results in a multi bill valuation if recce becomes a first in line defense as they say they exoect would be appropriate to eventuAte those numbers look clearly conservative the recent year/months revaluation trajectory is i very much believe just the start of an exponential rise in value but then i ve been saying this since 14c and 26 c now im really really saying it louder yes im a big investor and looking for more i lose sleep over not getting more at 68c recently as others but that miss is tiny to the gain ahead i feel sure cheers as always
RCE Price at posting:
$1.05 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)